Skip to content
OpenCapital
Get started

10x Genomics, Inc. TXG Debt Securities, Available For Sale, Amortized Cost Including Money Market Funds

Other financials

Income statement

See full
Revenue$150.8M-2.6%
Gross profit$106.2M+0.7%
Operating income-$17.0M+56.7%
Net income-$13.5M+60.8%
EPS (diluted)-$0.10+64.3%

Balance sheet

See full
Cash & equivalents$490.3M+30.0%
Total debt$81.4M+1.6%
Total equity$814.3M+15.2%
Total assets$1.0B+12.4%

Cash flow

See full
Operating cash flow$26.1M-24.0%
CapEx$1.6M-15.6%
Free cash flow$24.5M-24.4%

Valuation

See full
Market cap$4.41B+154%

Profitability

See full
Gross margin69.6%+1.2pp
Operating margin-6.1%-2.7pp
Net margin-3.5%-1.6pp
FCF margin19.1%—

Returns & leverage

See full
Return on equity-3%-1.4pp
Debt / equity0.1×0.0×
Current ratio5.9×+0.5×

Where this comes from

Reported directly by 10x Genomics, Inc. in its filing.

Tagged under the XBRL concept txg:DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds.

The official record: 10x Genomics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is 10x Genomics, Inc.'s debt securities, available for sale, amortized cost including money market funds?
10x Genomics, Inc. (TXG) reported debt securities, available for sale, amortized cost including money market funds of $509.86M in Q1 2026.
How has 10x Genomics, Inc.'s debt securities, available for sale, amortized cost including money market funds changed year-over-year?
10x Genomics, Inc.'s debt securities, available for sale, amortized cost including money market funds increased by 26.7% year-over-year, from $402.32M to $509.86M.
What is the long-term trend for 10x Genomics, Inc.'s debt securities, available for sale, amortized cost including money market funds?
Over 3 years (2022 to 2025), 10x Genomics, Inc.'s debt securities, available for sale, amortized cost including money market funds has grown at a 9.1% compound annual growth rate (CAGR), from $377.54M to $490.54M.